Dendritic cell vaccine (DC vaccine (DCV)[2])

A dendritic cell vaccine is a personalized or off-the-shelf immunotherapy that uses dendritic cells—professional antigen-presenting cells—to initiate antitumor immunity. DCs are generated ex vivo (commonly from monocytes with GM-CSF/IL-4), matured, and loaded with tumor antigens (peptides, proteins, tumor lysates, or mRNA), then administered to patients. After administration, mature DCs migrate to lymph nodes, present antigens on MHC I/II with costimulation, secrete cytokines (notably IL-12), and cross-prime CD8+ T cells, resulting in cytotoxic T lymphocytes and immunologic memory against cancer. Alternative strategies target or recruit DCs in vivo (e.g., anti-DEC-205 antigen delivery, Flt3L expansion, TLR agonists, biomaterial scaffolds). While safe and immunogenic, clinical efficacy has been variable, driving efforts to engineer cDC1-focused products, enhance migration and IL-12 production, and combine with adjuvants or checkpoint blockade to overcome tumor microenvironment suppression.

Other names

Dendritic cell-based vaccineDendritic cell cancer vaccineDC-based cancer vaccineAutologous dendritic cell vaccineMonocyte-derived dendritic cell vaccinecDC1-based dendritic cell vaccine

Ex vivo generated, antigen-loaded mature dendritic cells migrate to lymph nodes and present tumor antigens on MHC I/II with costimulation to prime tumor-specific CD8+ and CD4+ T cells, inducing effector function and memory; cross-presentation drives CTL responses; secreted cytokines (e.g., IL-12) promote Th1 immunity and NK/CTL activity. In vivo DC targeting/adjuvanting (e.g., DEC-205 targeting with TLR agonists; Flt3L expansion) enhances DC activation and T-cell responses.